

Freedom of Information Request	FOI 22-413	12 th September 2022
--------------------------------	------------	---------------------------------

The following question is being requested on behalf of Novartis. The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- Afatinib
- Alectinib
- Atezolizumab monotherapy
- Atezolizumab in combination
- Bevacizumab
- Brigatinib
- Capmatenib
- Ceritinib
- Crizotinib
- Dacomitinib
- Dabrafenib with Trametinib
- Docetaxel monotherapy
- Durvalumab
- Erlotinib
- Gefitinib
- Gemcitabine
- Nintedanib with Docetaxel
- Nivolumab
- Osimertinib
- Paclitaxel

- Pembrolizumab monotherapy
- Pembrolizumab in combination
- Pemetrexed with Carboplatin/Cisplatin
- Tepotinib
- Vinorelbine with Cisplatin/Carboplatin
- Any other SACT
- Palliative care only

The Health Board does not hold this information and would advise you to contact [Velindre University Health Board](#).